

Intra-Cellular Therapies, Inc.  
Form SC 13G/A  
February 05, 2015  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

---

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1)\*

Intra-Cellular Therapies, Inc.  
(Name of Issuer)

Common Stock, par value \$0.0001 per share  
(Title of Class of Securities)

46116X 101  
(CUSIP Number)

December 31, 2014  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
[X] Rule 13d-1(c)  
Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

Page 2 of 10

	NAMES OF REPORTING PERSONS	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)	
1	Morton I. Sosland	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [ ] (b) [X]
3	SEC USE ONLY	
	CITIZENSHIP OR PLACE OF ORGANIZATION	
4	United States of America	
	SOLE VOTING POWER	
	5	
	3,388,389	
NUMBER OF	SHARED VOTING POWER	
SHARES	6	
BENEFICIALLY	0	
OWNED BY	SOLE DISPOSITIVE POWER	
EACH	7	
REPORTING	3,388,389	
PERSON WITH	SHARED DISPOSITIVE POWER	
	8	
	0	
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING	
9	PERSON	
	3,388,389	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES	[ ]
	CERTAIN SHARES	
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
11	11.53%	
	TYPE OF REPORTING PERSON	
12	IN	

---

NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

1 David N. Sosland Trust A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [X]

3 SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

4 Missouri  
SOLE VOTING POWER  
5

NUMBER OF 707,287  
SHARES SHARED VOTING POWER  
BENEFICIALLY 6  
OWNED BY 0  
EACH SOLE DISPOSITIVE POWER

REPORTING 7  
PERSON WITH 707,287  
SHARED DISPOSITIVE POWER  
8  
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10 707,287  
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES [ ]  
CERTAIN SHARES  
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11 2.41%  
TYPE OF REPORTING PERSON

12 OO

NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

1 The Sosland Family Trust B Partnership

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [X]

3 SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

4 Missouri  
SOLE VOTING POWER  
5 1,948,554  
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
6 SHARED VOTING POWER  
7 0  
SOLE DISPOSITIVE POWER  
8 1,948,554  
SHARED DISPOSITIVE POWER  
9 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10 1,948,554  
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]  
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11 6.63%  
TYPE OF REPORTING PERSON

12 PN

NAMES OF REPORTING PERSONS  
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

1 The Sosland Foundation

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
 (b) [X]

3 SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

4 Missouri  
 SOLE VOTING POWER  
 5

NUMBER OF 732,548  
 SHARES SHARED VOTING POWER  
 BENEFICIALLY 6  
 OWNED BY 0  
 EACH SOLE DISPOSITIVE POWER  
 REPORTING 7

PERSON WITH 732,548  
 SHARED DISPOSITIVE POWER  
 8  
 0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10 732,548  
 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES [ ]  
 CERTAIN SHARES

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.49%  
 TYPE OF REPORTING PERSON

12 CO

Page 6 of 10

Item 1(a). Name of  
Issuer:

Intra-Cellular  
Therapies,  
Inc.

Item 1(b). Principal  
Executive  
Offices:

3960  
Broadway  
New York,  
New York  
10032

Items 2(a)  
and (b). Name of  
Persons  
Filing and  
Address of  
Principal  
Business  
Office:

Morton I.  
Sosland  
4801 Main  
Street, Suite  
650  
Kansas City,  
Missouri  
64112

David N.  
Sosland  
Trust A  
4801 Main  
Street, Suite  
650  
Kansas City,  
Missouri  
64112

Sosland  
Family Trust  
B

Partnership  
4801 Main  
Street, Suite  
650  
Kansas City,  
Missouri  
64112

The Sosland  
Foundation  
4801 Main  
Street, Suite  
650  
Kansas City,  
Missouri  
64112

Citizenship.

Morton I.  
Sosland is a  
citizen of the  
United States  
of America.

David N.  
Sosland  
Trust A is a  
Missouri  
trust.

Item 2(c).

Sosland  
Family Trust  
B  
Partnership  
is a Missouri  
partnership.

The Sosland  
Foundation  
is a Missouri  
non-profit  
corporation.

Item 2(d). Title of Class  
of Securities:

Common  
Stock, par  
value  
\$0.0001 per

share (the  
“Common  
Stock”)

Item 2(e). CUSIP  
Number:

46116X 101

Item 3. Not  
applicable.

---



Item 4. Ownership.

(a) Amount  
beneficially  
owned:

Morton I.  
Sosland is  
the  
beneficial  
owner of  
3,388,389  
shares of  
Common  
Stock.

The David  
N. Sosland  
Trust A is  
the  
beneficial  
owner of  
707,287  
shares of  
Common  
Stock.

The Sosland  
Family  
Trust B  
Partnership  
is the  
beneficial  
owner of  
1,948,554  
shares of  
Common  
Stock.

The Sosland  
Foundation  
is the  
beneficial  
owner of  
732,548  
shares of  
Common  
Stock.

(b) Percent of class:

Morton I. Sosland is the beneficial owner of 11.53% of the outstanding shares of Common Stock.

The David N. Sosland Trust A is the beneficial owner of 2.41% of the outstanding shares of Common Stock.

The Sosland Family Trust B Partnership is the beneficial owner of 6.63% of the outstanding shares of Common Stock.

The Sosland Foundation is the beneficial owner of 2.49% of the outstanding shares of Common Stock.

(c) Number of shares to which such person has power to vote, or direct the vote of, or to dispose, or to direct the disposition, of the shares:

As the Trustee of The David N. Sosland Trust A, Morton I. Sosland may direct the vote and disposition of all of the shares of Common Stock held by The David N. Sosland Trust.

As the Managing Partner of The Sosland Family Trust B Partnership, Morton I. Sosland may direct the vote and disposition of all of the shares of Common Stock held by The

Sosland  
Family  
Trust B  
Partnership.

As the Vice  
Chairman of  
The Sosland  
Foundation,  
Morton I.  
Sosland  
may direct  
the vote and  
disposition  
of all of the  
shares of  
Common  
Stock held  
by The  
Sosland  
Foundation.

Item 5. Ownership of Five  
Percent or Less of a  
Class.

Not applicable.

Item 6. Ownership of More  
than Five Percent on  
Behalf of Another  
Person.

Not applicable

Item 7. Identification and  
Classification of the  
Subsidiary Which  
Acquired the  
Security Being  
Reported By the  
Parent Holding  
Company.

Not applicable

Page 8 of 10

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of a Group.

Not applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits Exhibit A

Joint Filing  
Agreement  
dated  
September 9,  
2013, by and  
among  
Morton I.  
Sosland, The  
David N.  
Sosland Trust  
A, The  
Sosland  
Family Trust  
B Partnership  
and The  
Sosland  
Foundation.

---

Page 9 of 10

**SIGNATURE**

After reasonable inquiry and to the best of his or her knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: February 4, 2015

By: /s/ Morton I. Sosland  
Morton I. Sosland

David N. Sosland Trust A

By: /s/ Morton I. Sosland  
Morton I. Sosland, as Trustee

Sosland Family Trust B Partnership

By: /s/ Morton I. Sosland  
Morton I. Sosland, as Managing Partner

The Sosland Foundation

By: /s/ Morton I. Sosland  
Morton I. Sosland, as Vice Chairman

---

Page 10 of 10

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Intra-Cellular Therapies, Inc., and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

Dated: February 4, 2015

/s/ Morton I. Sosland  
Morton I. Sosland

David N. Sosland Trust A

By: /s/ Morton I. Sosland  
Morton I. Sosland, Trustee

Sosland Family Trust B Partnership

By: /s/ Morton I. Sosland  
Morton I. Sosland, Managing Partner

The Sosland Foundation

By: /s/ Morton I. Sosland  
Morton I. Sosland, Vice Chairman